Hanall Biopharma Co., Ltd.

Creabilis Therapeutics S.p.a.

Catalyst Biosciences, Inc.

Gilles Borrelly

Lila Drittanti

Thierry Guyon

Manuel Vega

Chiara Lorenzetto

Silvano Fumero

Luisa Bertarione Rava Rossa

Domenico Barone

Barbara Canepa

Xavier Gallet

Jorge Oyhenart

Domenico G Barone

Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.

Modified coagulation factor IX polypeptides and use thereof for treatment

Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.

Modified erythropoietin polypeptides and uses thereof for treatment

Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.

Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereof

The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.

HMGB1 high affinity binding domain Box-A mutants

Modified growth hormones

Modified growth hormone

Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A)

Growing community of inventors

Epinay-sous-Senart, France

Gilles Borrelly